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The incidence of invasive candidal infection is increasing. The
widespread use of central intravascular catheters, invasive
procedures, immunosuppression, diabetes mellitus, total paren-
teral nutrition, broad-spectrum antibiotics and drugs abuse
predispose patients to the infection. Eye, kidney, liver, skin, cardiac
and brain infections are the most common site of invasive
candidiasis while vertebral osteomyelitis is rare. Most Candida
vertebral osteomyelitis is caused by Candida albicans. Less common
organisms include C. tropicalis, C. glabrata and C. parapsilosis [1].
Both amphotericin B and the azoles have a role in the treatment,
but treatment failure with either agent had been reported [2,3].
Micafungin belongs to echinocandins, and interferes with the
synthesis of fungal cell wall.
We report a Candida tropicalis infection manifested with
osteomyelitis following a previous candidemia in a leukemia
patient who was successfully treated by Micafungin.
Case report
A 52 year-old man with acute myeloid leukemia received IA
(idarubicin + cytarabine) regimen of induction chemotherapy. His
bone marrow showed remission, then he received another three
consolidation chemotherapy. He experienced febrile neutropenia
and septic shock after a course of mid-dose Cytarabine and
recieved meropenem and voncomycin. Blood culture yielded
Candida tropicalis and he was treated with Micafungin for 2 weeks.
He had no fever and his leukocytes was nomal then he was
discharged from hospital after recovery.* Corresponding author.
E-mail address: maria2004mly@163.com (L. Ma).
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pain became more and more serious and a low-grade fever
developed. He couldn’t walk because of the pain. Even he felt pain
when he turned over. His physical examination was unremarkable
except for diffuse lumber midline and paraspinal muscle tender-
ness. After his readmission, his lumbar MRI showed severe
spondylodiscitis at L2–L3 and the formation of a vertebral abscess
(Fig. 1).
The patient was operated with debridement of infected lesion
and fusion of lumbar intervertebral space after general anesthesia.
L2 as the center, took the middle incision about 8 cm, exposed the
facet joints, opened, detected the pedicle was complete by probe,
implanted guide needle, then completed L2, L3 pedicle positioning
and implanted four screws. After decompression of vertebral plate,
nerve root was seen to adhere with surrounding tissue. The
intervertebral disc degenerated and the tissue was less than
normal. The inﬂammatory granulation tissue was seen and a small
amount of purulent package was sent to pathological examination.
L2/3 intervertebral space lesion was completely removed, and the
end plate was treated. The bones were cut into the size of rice for
ﬁlling in cage. Two cages was implanted in the intervertebral space,
ﬁxed with rod, thoroughly washed the incision, completely
stopped bleeding, stitched layer by layer, placed two tubes for
postoperative drainage. Pus culture yielded C. tropicalis and he
received Micafungin (150 mg/d, intravenous infusion) treatment
for over four months.
His low back pain resolved progressively with treatment. A
control lumbar MRI after four months of treatment and two
months of follow-up showed gradual improvement radiologically
and only the sequel lesions at the site of the infection (Fig. 2). His
white blood cells were 2.0–2.5*10E9/L, but his bone marrow
remained remission at the course of treatment and follow-up. Now
he can walk freely and return to normal life.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Magnetic resonance image of the dorsal spine showing an L2–L3 spondylodiscitis: T1-sagittal MRI image of the lumber spine reveals hypointense signal within the L2-
3 disc and associated destruction of vertebral bodies and compromise of the spinal cord at this level (A). T2 sagittal MRI reveals hyperintense marrow signal (B).
Fig. 2. A control lumbar MRI after two months of treatment (C) and four months of follow-up (D) showed gradual improvement radiologically and only the sequel lesions at
the site of the infection (T2 sagittal).
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This patient was a middle-aged man with leukemia. Fever and
lumber pain were his main complaint. He had several risk factors:
broad-spectrum antibiotic usage, CVC, immunosusppression,
malignancy and candidemia. The time interval from candidemia
to identiﬁcation of Candida osteomyelitis was about two months. It
is possible that the complications experienced by this patient
could have been averted with adequate treatment of the initial
candidemia.
The diagnosis of candidal vertebral osteomyelitis begins with a
high clinical index of suspicion, followed by appropriate radio-
graphic studies and conﬁrmation with microbiological tests [3].
MRI is more sensitive, speciﬁc and accurate than radioisotope bone
scan or CT scan for early recognition and localization of infectious
disease. Lifeso et al. found MRI to be 96% sensitive, 92% speciﬁc and94% accurate in the diagnosis of vertebral osteomyelitis. In
addition, MRI is an excellent way of demonstrating the presence
of epidural or paraspinal extension of the infection [4]. Thus, MRI
studies may lead to early diagnosis and differential diagnosis from
degenerative disc disease, malignancy and tuberculosis.
A review of Candida osteomyelitis cases reported in the
literature showed C. albicans as the predominant species (69%),
followed by C. tropicalis (15%) and C. glabrata (8%). Fifty-seven
percent of patients underwent a combination of surgical and
antifungal therapy with therapy reported to be successful in 88%
[5–7].
Amphotericin B has historically been the most commonly used
antifungal therapy for Candida infections, but there appears to be a
trend toward the use of azoles and echinocandins. However, there
are very limited data available to support using echinocandins as
therapy for candidal osteomyelitis. A review of literature revealed
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tis, all treated successfully with caspofugin [5,8,9]. So far there is no
reported cases of treatment with micafungin for C. tropical
osteomyelitis.
Micafungin as one kind of echinocandins, is indicated for the
treatment of candidemia, acute disseminated candidiasis, candida
peritonitis, abscesses and esophageal candidiasis [10,11]. Mica-
fungin has been approved for the prophylaxis of candida infections
in patients undergoing hematopoietic stem cell transplantation.
Micafungin works by way of concentration-dependent inhibition
of 1,3-beta-D-glucan synthesis resulting in reduced formation of
1,3-beta-D-glucan, which is an essential polysaccharide comprising
one-third of the majority of candida spp. cell walls. This decreased
glucan production leads to osmotic instability and thus cellular
lysis [10,11].
Micafugin are better than Amphotericin B in terms of
nephrotoxicity, liver enzyme changes, and general side effects,
including fever, chills, nausea, vomiting, and dyspnea. We reveal
that micafugin has no evident side effect in this patient and plays a
great role in his symptoms relief and radiograﬁc improvement.
Long-term therapy with micafugin is generally well-tolerated and
can be continued for longer than 4 months.
Surgical intervention was generally used to make a deﬁnitive
diagnosis when examination of biopsy specimen was not
diagnostic, to decompress the spinal canal when radiographic or
clinical features suggested spinal cord impingement, or to provide
stability in the face of extensive disease [3]. Combination
treatment of antifugal agents and surgical debridement and
sufﬁcient drainage is a better way to treat Candida osteomyelitis.
Prompt diagnosis and appropriate treatment are associated
with a good prognosis. The prognosis for patients with candidal
vertebral osteomyelitis appears to be favorable, with an overall
cure rate of candidal vertebral osteomyelitis of 85%. The majority of
patients were clinically cured in the absence of signiﬁcant
comorbidities [3].
Conclusion
To our knowledge, this is the ﬁrst case report that Micafungin
successfully treated Candida tropicalis osteomyelitis in a leukemia
patient. Although Candida tropicalis are a rare cause of vertebral
osteomyelitis, clinicians must suspect this entity in patientspresenting with risk factors for candidiasis and low back pain of
long duration. Once diagnosed, it should be aggressively treated
with combination of medical and surgical management. Histori-
cally amphotericin B was the most frequently used agent, followed
by ﬂucytosine. Now more options are available. Micafugin as a new
agent showed a great role in treatment of this patient. There is
need for further research on the appropriate length of treatment
with Micafugin for Candida tropicalis osteomyelitis [3].
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